论文信息 - Cost of exome analysis in patients with intellectual disability: a micro-costing study in a French setting - 字舞流文

Cost of exome analysis in patients with intellectual disability: a micro-costing study in a French setting

A. Toutain | N. Philip | P. Jouk | A. Boland | D. Lacombe | L. Pasquier | E. Colin | J. Thevenon | S. Mercier | L. Faivre | S. Blesson | B. Gérard | C. Thauvin-Robinet | A. Piton | Y. Duffourd | C. Besse | S. Moutton | M. Fradin | C. Binquet | S. Odent | C. Coubes | M. Doco‐Fenzy | A. Goldenberg | P. Blanchet | D. Geneviève | B. Leheup | F. Petit | A. Putoux | A. Lavillaureix | M. Vincent | P. Edery | F. Devillard | C. Quélin | S. El Chehadeh | A. Guerrot | M. Nizon | L. Pinson | N. Jean-Marçais | M. Legendre | J. Deleuze | S. Manouvrier | N. Houcinat | A. Sorlin | S. Arpin | M. Willems | L. Pons | J. Van-Gils | T. Busa | C. Vanlerberghe | B. Isidor | O. Boute‐Bénéjean | J. Muller | A. Ziegler | L. Lambert | C. Vincent-Delorme | T. Jouan | C. Poirsier | M. Spodenkiewicz | D. Bacq-Daian | M. Rossi | Y. Herenger | C. Pöe | A. Verloes | A. Soilly | C. Robert-Viard | AL Bruel | S. El Doueiri | ML Asensio | S P S O T E C F P S M A A-M Y N N P. S. L A M B S S Arpin Blanchet Blesson Boute-Benejean Busa Coli | M. Renaud | C. Lejeune

[1] C. Lejeune,et al. Genome Sequencing for Genetics Diagnosis of Patients With Intellectual Disability: The DEFIDIAG Study , 2022, Frontiers in Genetics.

[2] M. Ducreux,et al. Accès aux tests génétiques en oncologie , 2022, Bulletin de l'Académie Nationale de Médecine.

[3] E. Solary,et al. Whole exome sequencing in molecular diagnostics of cancer decreases over time: evidence from a cost analysis in the French setting , 2021, The European Journal of Health Economics.

[4] E. Cuppen,et al. Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE) , 2020, BMC medical genomics.

[5] S. Scherer,et al. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders , 2019, Genetics in Medicine.

[6] P. Donnelly,et al. The UK Biobank resource with deep phenotyping and genomic data , 2018, Nature.

[7] C. Depienne,et al. Using medical exome sequencing to identify the causes of neurodevelopmental disorders: Experience of 2 clinical units and 216 patients , 2018, Clinical genetics.

[8] L. Lynd,et al. The cost and diagnostic yield of exome sequencing for children with suspected genetic disorders: a benchmarking study , 2018, Genetics in Medicine.

[9] Daniele Merico,et al. A microcosting and cost–consequence analysis of clinical genomic testing strategies in autism spectrum disorder , 2017, Genetics in Medicine.

[10] Gert Jan van der Wilt,et al. A clinical utility study of exome sequencing versus conventional genetic testing in pediatric neurology , 2017, Genetics in Medicine.

[11] Joshua Burns,et al. Cost-effectiveness of massively parallel sequencing for diagnosis of paediatric muscle diseases , 2017, npj Genomic Medicine.

[12] Clara Gaff,et al. Prospective comparison of the cost-effectiveness of clinical whole-exome sequencing with that of usual care overwhelmingly supports early use and reimbursement , 2017, Genetics in Medicine.

[13] Gert Jan van der Wilt,et al. Is the $1000 Genome as Near as We Think? A Cost Analysis of Next-Generation Sequencing. , 2016, Clinical chemistry.

[14] Shivang Doshi,et al. Genomic Sequencing Procedure Microcosting Analysis and Health Economic Cost-Impact Analysis , 2016, The Journal of molecular diagnostics : JMD.

[15] Anke M Hövels,et al. Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability , 2016, Genetics in Medicine.

[16] J. Schieving. PP05.5 – 3064: The role of exome sequencing in daily pediatric neurology practice , 2015 .

[17] Véronique Geoffroy,et al. Efficient strategy for the molecular diagnosis of intellectual disability using targeted high-throughput sequencing , 2014, Journal of Medical Genetics.

[18] H. G. Grossetta Nardini,et al. Micro-costing studies in the health and medical literature: protocol for a systematic review , 2014, Systematic Reviews.

[19] P. Froguel,et al. Highly Sensitive Diagnosis of 43 Monogenic Forms of Diabetes or Obesity Through One-Step PCR-Based Enrichment in Combination With Next-Generation Sequencing , 2014, Diabetes Care.

[20] Christian Gilissen,et al. A Post‐Hoc Comparison of the Utility of Sanger Sequencing and Exome Sequencing for the Diagnosis of Heterogeneous Diseases , 2013, Human mutation.

[21] Mustafa Tekin,et al. The promise of whole-exome sequencing in medical genetics , 2013, Journal of Human Genetics.

[22] David L Veenstra,et al. The economics of genomic medicine: insights from the IOM Roundtable on Translating Genomic-Based Research for Health. , 2013, JAMA.

[23] A. Afenjar,et al. [Diagnostic investigations for an unexplained developmental disability]. , 2012, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[24] A. Verloes,et al. Stratégie d’exploration d’une déficience intellectuelle inexpliquée , 2012 .

[25] Andrew B Singleton,et al. Exome sequencing: a transformative technology , 2011, The Lancet Neurology.

[26] Kevin D Frick,et al. Microcosting Quantity Data Collection Methods , 2009, Medical care.

[27] F. Rutten,et al. Comparing methodologies for the cost estimation of hospital services , 2009, The European Journal of Health Economics.

[28] Grazyna Adamiak,et al. Methods for the economic evaluation of health care programmes, 3rd ed , 2006 .

[29] S. Wilson. Methods for the economic evaluation of health care programmes , 1987 .

[30] C. Rose,et al. Institut National de la Santé et de la Recherche Médicale , 1976 .

[31] MA Katharina Schwarze BSc,et al. Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature , 2018, Genetics in Medicine.

[32] P. Guerre,et al. [Hospital costs estimation by micro and gross-costing approaches]. , 2018, Revue d'epidemiologie et de sante publique.

[33] Dede Sika Kossi,et al. Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study , 2017, European Journal of Human Genetics.